Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma

SummaryThe patient presented here was diagnosed with multifocal primary cutaneous anaplastic large-cell lymphoma at the age of 80  years. Initially, he received chemotherapy plus prednisolone, which had to be discontinued due to toxicity. Treatment with brentuximab vedotin was then commenced, which promoted reductions in skin lesions of the patient, and was well tolerated. New lesions occurred 6 months after the start of bre ntuximab vedotin therapy, but were successfully controlled with irradiation. The patient experienced sustained disease control with ongoing brentuximab vedotin administration for more than 1 year. His quality of life is not compromised by this treatment in spite of his advanced age.

Source: Memo - Magazine of European Medical Oncology - March 27, 2017 Category: Cancer & Oncology Source Type: research